Cargando…
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
Despite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151905/ https://www.ncbi.nlm.nih.gov/pubmed/34066684 http://dx.doi.org/10.3390/medicina57050458 |